Cost-Effectiveness of Old and New Technologies for Aneuploidy Screening

Academic Article

Abstract

  • © 2016 Elsevier Inc. Cost-effectiveness analyses allow assessment of whether marginal gains from new technology are worth increased costs. Several studies have examined cost-effectiveness of Down syndrome (DS) screening and found it to be cost-effective. Noninvasive prenatal screening also appears to be cost-effective among high-risk women with respect to DS screening, but not for the general population. Chromosomal microarray (CMA) is a genetic sequencing method superior to but more expensive than karyotype. In light of CMAs greater ability to detect genetic abnormalities, it is cost-effective when used for prenatal diagnosis of an anomalous fetus. This article covers methodology and salient issues of cost-effectiveness.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Sinkey RG; Odibo AO
  • Start Page

  • 237
  • End Page

  • 248
  • Volume

  • 36
  • Issue

  • 2